Title | Antifolate Drugs in Cancer Therapy [electronic resource] / edited by Ann L. Jackman |
---|---|
Imprint | Totowa, NJ : Humana Press : Imprint: Humana Press, 1999 |
Connect to | http://dx.doi.org/10.1007/978-1-59259-725-3 |
Descript | X, 456 p. online resource |
1 Antifolate Drugs: Past and Future Perspectives -- 2 Folate Biochemistry in Relation to Antifolate Selectivity -- 3 Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors -- 4 Development of Nonpolyglutamatable DHFR Inhibitors -- 5 Fluoropyrimidines as Antifolate Drugs -- 6 Raltitrexed (Tomudextm), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor: Design and Preclinical Activity -- 7 Tomudex: Clinical Development -- 8 Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514) -- 9 GW1843: A Potent, Noncompetitive Thymidylate Synthase InhibitorโPreclinical and Preliminary Clinical Studies -- 10 Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed Dihydrochloride (Thymitaqtm, AG337) -- 11 ZD9331: Preclinical and Clinical Studies -- 12 Preclinical and Clinical Evaluation of the Glycinamide Ribonucleotide Formyltransferase Inhibitors Lometrexol and LY309887 -- 13 AG2034: A GARFT Inhibitor with Selective Cytotoxicity to Cells that Lack a G1 Checkpoint -- 14 Receptor- and Carrier-Mediated Transport Systems for Folates and Antifolates: Exploitation for Folate-Based Chemotherapy and Immunotherapy -- 15 Folates as Chemotherapeutic Modulators -- 16 Antifolate Polyglutamylation in Preclinical and Clinical Antifolate Resistance -- 17 Antifolates in Combination Therapy -- 18 Pharmacodynamic Measurements and Predictors of Response to Thymidylate Synthase Inhibitors -- 19 Molecular Regulation of Expression of Thymidylate Synthase -- 20 The Role of Uracil Misincorporation in Thymineless Death -- 21 Thymineless Death -- 22 Genetic Determinants of Cell Death and Toxicity